Nexus Pharmaceuticals Announces Launch of Tacrolimus Injection
We’re proud to share the news of our latest product launch: Tacrolimus Injection, USP 5 mg/mL, now available in a single-dose vial format. This critical immunosuppressant is indicated for the prevention of organ rejection in liver and kidney transplant patients, offering healthcare providers a new, cost-effective option in a convenient presentation. This launch represents another step […]
Nexus Pharmaceuticals Launches Baclofen Injection Refill Kit
Nexus Pharmaceuticals introduces the Baclofen Injection Refill Kit, the only vial-based option on the market, offering a convenient solution for healthcare providers managing patients with long-term severe spasticity.
Nexus Pharmaceuticals Launches Fluorescein 2 mL
Nexus Pharmaceuticals introduces a 2 mL vial of Fluorescein Injection, USP 25%, enhancing diagnostic options for eye care professionals and reinforcing its commitment to specialty injectable solutions.
Nexus Pharmaceuticals Launches Tranexamic Acid
Nexus Pharmaceuticals announces the launch of Tranexamic Acid Injection, an antifibrinolytic agent essential for surgical bleeding control, now available in cartons of 10 bags through wholesalers.
Nexus Pharmaceuticals Receives FDA Approval for Tacrolimus Injection
Nexus Pharmaceuticals announces FDA approval of its Tacrolimus Injection 5 mg/mL, the first and only vial formulation available, enhancing treatment options for patients requiring immunosuppressive therapy.
Nexus Pharmaceuticals Receives FDA Approval for Methylene Blue Injection, USP
Nexus Pharmaceuticals announces FDA approval of its Methylene Blue Injection, USP, for the treatment of acquired methemoglobinemia, reinforcing its commitment to delivering critical, life-saving medications.